Tomas Mlcoch
Overview
Explore the profile of Tomas Mlcoch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mlcoch T, Decker B, Tuzil J, Turkova B, Doleckova K, Koznarova B, et al.
Value Health Reg Issues
. 2025 Feb;
47:101085.
PMID: 39933437
Objectives: This study aimed to provide the first evidence of the socioeconomic burden of cystic fibrosis (CF) in Czechia. Methods: In a cross-sectional questionnaire-based primary data collection conducted from 2020...
2.
Decker B, Mlcoch T, Pustovalova A, Dolezal T
Int J Technol Assess Health Care
. 2023 Feb;
39(1):e10.
PMID: 36748356
Background: Out of 185 orphan medicinal products (OMPs) registered in 2015-2021, a mere 110 (59 percent) were available to Czech patients, and only 54 (29 percent) were officially reimbursed. Moreover,...
3.
Ornstova E, Tuzil J, Chadimova K, Mlcoch T, Dolezal T
Expert Rev Pharmacoecon Outcomes Res
. 2022 Sep;
22(8):1269-1275.
PMID: 36121156
Objectives: The comparative efficacy between riociguat and selexipag in patients with pulmonary arterial hypertension (PAH) has never been described in literature. Our aim was to prepare indirect treatment comparison (ITC)...
4.
Tuzil J, Mlcoch T, Zavada J, Svoboda M, Pavelka K, Dolezal T
Rheumatology (Oxford)
. 2021 Oct;
61(6):2295-2306.
PMID: 34599798
Objective: Achieving targeted disease activity (DA) is the primary therapeutic strategy in RA. Point measurements of DA are done at out-patient visits, however true DA between visits remains unobserved. This...
5.
Mlcoch T, Decker B, Dolezal T
Appl Health Econ Health Policy
. 2021 Jan;
19(4):593-604.
PMID: 33426625
Background: Despite worldwide use of parenteral methotrexate (pMTX), health economic evidence for its use in Crohn's disease (CD) is limited. The low price of this generic drug has removed any...
6.
Fiala O, Finek J, Poprach A, Melichar B, Kopecky J, Zemanova M, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32230921
Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies,...
7.
Mlcoch T, Hrnciarova T, Tuzil J, Zadak J, Marian M, Dolezal T
Value Health
. 2019 Dec;
22(12):1370-1377.
PMID: 31806193
Background: In situations of markedly different population characteristics and weak population overlap, inverse propensity score (PS) weights suffer from extreme values. The new propensity score weighting method using overlap weights...
8.
Tuzil J, Mlcoch T, Jircikova J, Zavada J, Nekvindova L, Svoboda M, et al.
Expert Opin Biol Ther
. 2019 Nov;
20(2):183-192.
PMID: 31736377
: To assess the role of short-term response to first anti-TNF in long-term prediction of disability.: In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and...
9.
Ornstova E, Sebestianova M, Mlcoch T, Lamblova K, Dolezal T
Value Health Reg Issues
. 2018 Oct;
16:92-98.
PMID: 30316030
Background: Highly innovative drugs (HIDs) can be granted 2 to 3 years of temporary reimbursement (TR) to provide timely patient access and to collect real-world evidence through registries in the...
10.
Klimes J, Vocelka M, Sedova L, Dolezal T, Mlcoch T, Petrikova A, et al.
Value Health Reg Issues
. 2018 Apr;
4:75-81.
PMID: 29702811
Objective: International pharmacoeconomic studies suggest that functional impairment can be a significant predictor for the evaluation of direct and productivity costs for rheumatoid arthritis (RA). We calculated the direct and...